Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

JPMorgan maintains overweight rating on Dynatrace with $60 target

EditorBrando Bricchi
Published 05/21/2024, 01:02 AM
DT
-

On Monday, JPMorgan reiterated its Overweight rating with a $60.00 price target for Dynatrace Inc. (NYSE:DT). The firm's position remains positive following Dynatrace's early announcement of data from their clinical studies. Dynatrace disclosed results from the ACHIEVE and DELIVER studies, which evaluate treatments for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively.

The company chose to release this information ahead of the second half of 2024 due to the compelling nature of the data and encouraging regulatory interactions. The ACHIEVE study, with data from 56 enrolled participants as of May 8, 2024, and the DELIVER study, with data from 48 young patients as of April 30, 2024, showed promising safety and tolerability profiles.

Efficacy outcomes from the ACHIEVE study cohorts were measured at around 12 months, 6 months, and 3 months for different dosage groups. The DELIVER study provided pharmacokinetic and pharmacodynamic data, including dystrophin expression levels, from a cohort at approximately 6 months.

Dyne is aiming for expedited approval processes for both treatment programs, with plans to update on the pathways to registration by the end of 2024. JPMorgan views these developments as positive enhancements to the profiles of the treatments and anticipates further long-term data as additional patient results become available. The firm's ongoing support is based on the potential of Dynatrace's FORCE TfR1-targeting platform to address significant unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.